Centro Hospitalar Universitário São João,EPE

Porto 4202-451

4 studies enrolling now · 12 studies all time

What they study most

Bronchiectasis, Cardiovascular Diseases, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Heart Failure, Hypertension, Idiopathic Pulmonary Fibrosis, Kidney Disease, Chronic, Leukemia, Myeloid, Acute, Lung Diseases, Interstitial, Lupus Nephritis, Non-alcoholic Steatohepatitis (NASH)

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis — Recruiting now
• The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis — Recruiting now
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
• Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis — Completed
• A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) — Completed
• A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease — Completed
• A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis — Completed
• Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) — Completed
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms. — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms — Completed